112 related articles for article (PubMed ID: 24417912)
21. Early M-protein immune reconstitution after autologous haematopoietic stem cell transplantation is a good prognostic marker for patients with high-risk cytogenetic multiple myeloma.
Zhu H; Liu J; Gu J; Chen M; Kuang L; Huang B; Zou W; Li J
Br J Haematol; 2024 Mar; 204(3):976-987. PubMed ID: 38246862
[TBL] [Abstract][Full Text] [Related]
22. Older patients with myeloma derive similar benefit from autologous transplantation.
Sharma M; Zhang MJ; Zhong X; Abidi MH; Akpek G; Bacher U; Callander NS; Dispenzieri A; Freytes CO; Fung HC; Gale RP; Gasparetto C; Gibson J; Holmberg LA; Kindwall-Keller TL; Klumpp TR; Krishnan AY; Landau HJ; Lazarus HM; Lonial S; Maiolino A; Marks DI; Mehta P; Mikhael Med JR; Nishihori T; Olsson R; Ramanathan M; Roy V; Savani BN; Schouten HC; Scott E; Tay J; To LB; Vesole DH; Vogl DT; Hari P
Biol Blood Marrow Transplant; 2014 Nov; 20(11):1796-803. PubMed ID: 25046833
[TBL] [Abstract][Full Text] [Related]
23. A prospective study of dysgeusia and related symptoms in patients with multiple myeloma after autologous hematopoietic cell transplantation.
Scordo M; Shah GL; Adintori PA; Knezevic A; Devlin SM; Buchan ML; Preston EV; Lin AP; Rodriguez NT; Carino CA; Nguyen LK; Sitner NC; Barasch A; Klang MG; Maloy MA; Mastrogiacomo B; Carlow DC; Schofield RC; Slingerland AE; Slingerland JB; Stein-Thoeringer CK; Lahoud OB; Landau HJ; Chung DJ; van den Brink MRM; Peled JU; Giralt SA
Cancer; 2022 Nov; 128(21):3850-3859. PubMed ID: 36041227
[TBL] [Abstract][Full Text] [Related]
24. The Arkansas approach to therapy of patients with multiple myeloma.
Barlogie B; Anaissie E; van Rhee F; Pineda-Roman M; Zangari M; Shaughnessy J; Epstein J; Crowley J
Best Pract Res Clin Haematol; 2007 Dec; 20(4):761-81. PubMed ID: 18070718
[TBL] [Abstract][Full Text] [Related]
25. Genomic Classification and Individualized Prognosis in Multiple Myeloma.
Maura F; Rajanna AR; Ziccheddu B; Poos AM; Derkach A; Maclachlan K; Durante M; Diamond B; Papadimitriou M; Davies F; Boyle EM; Walker B; Hultcrantz M; Silva A; Hampton O; Teer JK; Siegel EM; Bolli N; Jackson GH; Kaiser M; Pawlyn C; Cook G; Kazandjian D; Stein C; Chesi M; Bergsagel L; Mai EK; Goldschmidt H; Weisel KC; Fenk R; Raab MS; Van Rhee F; Usmani S; Shain KH; Weinhold N; Morgan G; Landgren O
J Clin Oncol; 2024 Apr; 42(11):1229-1240. PubMed ID: 38194610
[TBL] [Abstract][Full Text] [Related]
26. Early relapse after single auto-SCT for multiple myeloma is a major predictor of survival in the era of novel agents.
Jimenez-Zepeda VH; Reece DE; Trudel S; Chen C; Tiedemann R; Kukreti V
Bone Marrow Transplant; 2015 Feb; 50(2):204-8. PubMed ID: 25347006
[TBL] [Abstract][Full Text] [Related]
27. Long-Term Responders After Autologous Stem Cell Transplantation in Multiple Myeloma.
Oliver-Caldes A; Soler-Perromat JC; Lozano E; Moreno D; Bataller A; Mozas P; Garrote M; Setoain X; Aróstegui JI; Yagüe J; Tovar N; Jiménez R; Rodríguez-Lobato LG; Cibeira MT; Rosiñol L; Bladé J; Juan M; Fernández de Larrea C
Front Oncol; 2022; 12():936993. PubMed ID: 35865461
[TBL] [Abstract][Full Text] [Related]
28. Spotlight on Melphalan Flufenamide: An Up-and-Coming Therapy for the Treatment of Myeloma.
Morabito F; Tripepi G; Martino EA; Vigna E; Mendicino F; Morabito L; Todoerti K; Al-Janazreh H; D'Arrigo G; Canale FA; Cutrona G; Neri A; Martino M; Gentile M
Drug Des Devel Ther; 2021; 15():2969-2978. PubMed ID: 34262262
[TBL] [Abstract][Full Text] [Related]
29. Oncolytic measles virus therapy enhances tumor antigen-specific T-cell responses in patients with multiple myeloma.
Packiriswamy N; Upreti D; Zhou Y; Khan R; Miller A; Diaz RM; Rooney CM; Dispenzieri A; Peng KW; Russell SJ
Leukemia; 2020 Dec; 34(12):3310-3322. PubMed ID: 32327728
[TBL] [Abstract][Full Text] [Related]
30. Soluble PD-L1: A biomarker to predict progression of autologous transplantation in patients with multiple myeloma.
Huang SY; Lin HH; Lin CW; Li CC; Yao M; Tang JL; Hou HA; Tsay W; Chou SJ; Cheng CL; Tien HF
Oncotarget; 2016 Sep; 7(38):62490-62502. PubMed ID: 27566569
[TBL] [Abstract][Full Text] [Related]
31. Minimal Residual Disease Assessment in the Context of Multiple Myeloma Treatment.
Nishihori T; Song J; Shain KH
Curr Hematol Malig Rep; 2016 Apr; 11(2):118-26. PubMed ID: 26898557
[TBL] [Abstract][Full Text] [Related]
32. Curing myeloma at last: defining criteria and providing the evidence.
Barlogie B; Mitchell A; van Rhee F; Epstein J; Morgan GJ; Crowley J
Blood; 2014 Nov; 124(20):3043-51. PubMed ID: 25293776
[TBL] [Abstract][Full Text] [Related]
33. Controversies in multiple myeloma: to transplant or not?
Preeshagul IR; Van Besien K; Mark TM
Curr Hematol Malig Rep; 2014 Dec; 9(4):360-7. PubMed ID: 25145553
[TBL] [Abstract][Full Text] [Related]
34. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation.
Kim JS; Kim K; Cheong JW; Min YH; Suh C; Kim H; Jo DY; Ryoo HM; Yoon SS; Lee JH;
Biol Blood Marrow Transplant; 2009 Apr; 15(4):463-70. PubMed ID: 19285634
[TBL] [Abstract][Full Text] [Related]
35. Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99-02 and 99-04 Trials.
Harousseau JL; Avet-Loiseau H; Attal M; Charbonnel C; Garban F; Hulin C; Michallet M; Facon T; Garderet L; Marit G; Ketterer N; Lamy T; Voillat L; Guilhot F; Doyen C; Mathiot C; Moreau P
J Clin Oncol; 2009 Dec; 27(34):5720-6. PubMed ID: 19826130
[TBL] [Abstract][Full Text] [Related]
36. [Treatment options and prognosis in newly diagnosed multiple myeloma patients].
Wang L; Tang W; Wang Y; Xu L; Zhao WL; Wu W; Chen YB; Shen ZX; Hu J
Zhonghua Xue Ye Xue Za Zhi; 2011 May; 32(5):308-12. PubMed ID: 21729598
[TBL] [Abstract][Full Text] [Related]
37. Treatment of multiple myeloma.
San Miguel JF; Bladé Creixenti J; García-Sanz R
Haematologica; 1999 Jan; 84(1):36-58. PubMed ID: 10091392
[TBL] [Abstract][Full Text] [Related]
38. [Progress in the treatment of multiple myeloma].
Wada M; Mizoguchi H
Gan To Kagaku Ryoho; 1997 Jul; 24(9):1079-88. PubMed ID: 9239160
[TBL] [Abstract][Full Text] [Related]
39. Long-term results in multiple myeloma after high-dose melphalan and autologous transplantation according to response categories in the era of old drugs.
Martino M; Postorino M; Gallo GA; Messina G; Neri S; Piro E; Gentile M; Moscato T; Monteleone R; Fedele R; Mazzone C; Console G; Penna G; Alati C; Vincelli ID; Irrera G; Musolino C; Ronco F; Molica S; Morabito F
Clin Lymphoma Myeloma Leuk; 2014 Apr; 14(2):148-54. PubMed ID: 24417912
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
